A Multi-center, Randomized, Vehicle-Controlled Study to Assess the Efficacy and Safety of Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment (BELIEVE).

Trial Profile

A Multi-center, Randomized, Vehicle-Controlled Study to Assess the Efficacy and Safety of Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment (BELIEVE).

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Adalimumab (Primary) ; Betamethasone-dipropionate/calcipotriol
  • Indications Plaque psoriasis; Psoriatic arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BELIEVE
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 08 Mar 2016 Results (n=205) assessing baseline characteristics presented at the 74th Annual Meeting of the American Academy of Dermatology
    • 08 Mar 2016 Results (pooled subgroup analysis of this and other 3 phase III studies, n = 1558) presented at the 74th Annual Meeting of the American Academy of Dermatology.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top